POSIFLEX-TECHNOLOGY
15.3.2024 03:28:35 CET | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce that its Haydn ZT Series - the industry's first clamshell POS terminal with a patented modular design and exceptional serviceability - and its Gen9 Base, which integrates a thermal printer and power supply for maximum space efficiency, have been awarded the iF DESIGN AWARD 2024 in the discipline of Product in the Public/Retail category by the Hannover-based iF International Forum Design GmbH, which is one of the most coveted accolades in the world of design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314845350/en/
Posiflex Wins the iF DESIGN AWARD 2024 for Haydn ZT Series and Gen9 Base (Graphic: Business Wire)
The Posiflex Haydn ZT Series and Gen9 Base stood out from a field of nearly 11,000 entries from 72 countries, impressing the 132-strong jury of independent experts from around the world with innovative designs and technical excellence aimed at delivering the highest levels of convenience and value to users and consumers.
Haydn ZT Series: The Industry's First Clamshell POS Terminal
The Posiflex Haydn ZT Series redefines the mechanical structure of POS terminals with the world's first clamshell design. This design simplifies maintenance tasks by allowing the monitor to be effortlessly lifted with just a slide of the hidden lever. It provides convenient access to internal modular components and facilitates easy and seamless repairs, replacements, and upgrades. Such innovation promises to significantly reduce downtime in case of a crash, minimizing inconvenience and financial losses associated with such incidents.
Gen9 Base: A Multi-Functional POS Terminal Base
The Gen9 Base is a multi-functional POS terminal base that integrates a built-in high-speed 250mm/second thermal receipt printer with auto-cutter concealed within its lightweight, screwless housing, in addition to hidden I/O, power and cabling designs, all of which combine to achieve a clean and stylish look and a clutter-free countertop. The POS terminal base also offers the option of a second monitor, expandable up to 15.6 inches, for maximum space efficiency and convenience for users and consumers.
Owen Chen, CEO of Posiflex Technology remarked, "Winning the iF DESIGN AWARD 2024 for our Haydn ZT Series and Gen9 Base is a testament to Posiflex's relentless pursuit of excellence in product design and innovation. Posiflex has been committed to pushing the boundaries of technological innovation to enhance the experiences of our customers worldwide.”
Being recognized by the esteemed iF International Forum Design GmbH reaffirms our position as a leader in the industry and motivates us to continue delivering cutting-edge solutions that meet the evolving needs of our customers. The Haydn ZT POS terminal series and Gen9 Base epitomize our dedication to innovation-driven entrepreneurship and unwavering focus on putting our customers first.
More information about The Haydn ZT Series and Gen9 Base can be found at: https://ifdesign.com/en/search?find=posiflex
About POSIFLEX Group
Posiflex Group is a leading global Commercial Internet of Things (CIoT) platform powered by smart Online-to-Offline (O2O) and Software-agnostic Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314845350/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom